Beraprost

CAS : 88430-50-6

Ref. 3D-FB167395

Informations sur le produit

• Nom: Beraprost
• Synonymes: 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-yn-1-yl)-, 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, 2,3,3a,8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-yn-1-yl)-1H-cyclopenta[b]benzofuran-5-butanoic acid, 4-{(1R,2R,3aS,8bS)-2-hydroxy-1-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl}butanoic acid, 4-{2-hydroxy-1-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl}butanoic acid, Mdl 201229, Ml 1229

Description

Beraprost is a prostacyclin analogue that is used in the treatment of primary pulmonary hypertension. It has been shown to be effective in the treatment of chronic bowel disease and low-dose group. Beraprost sodium binds to the response element, preventing the binding of transcription factors and inhibiting gene expression. The pyrazole ring is an analogue of prostacyclin that has been shown to inhibit blood clotting as well as brain functions. Beraprost also inhibits platelet aggregation and leukocyte adhesion, thereby reducing inflammation and vascular permeability. Beraprost can be taken orally or by injection.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 398.49 g/mol
• Formule: C₂₄H₃₀O₅
• Degré de pureté: Min. 95%